Galmed Pharmaceuticals (GLMD) Non-Current Debt (2013 - 2016)

Galmed Pharmaceuticals (GLMD) recorded quarterly Non-Current Debt of $796000.0 in Q4 2016, up 85.98% quarter-over-quarter from $428000.0 in Q4 2013.

Galmed Pharmaceuticals (GLMD) Non-Current Debt (2013 - 2016) Analysis & Trends

Galmed Pharmaceuticals' Non-Current Debt history runs 2 years deep, the most recent figure standing at $796000.0 for Q4 2016.

In Q4 2016, Non-Current Debt changed N/A year-over-year to $796000.0; the TTM figure through Dec 2016 stood at $796000.0 (changed N/A YoY), while the FY2016 annual figure was $796000.0, changed N/A from the prior year.
Non-Current Debt was $796000.0 for Q4 2016 at Galmed Pharmaceuticals, up from $428000.0 in the prior quarter.
In the past five years, Non-Current Debt ranged from a high of $796000.0 in Q4 2016 to a low of $428000.0 in Q4 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	319.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Galmed Pharmaceuticals	2.48 Mn	-1.63 Mn	-	-

Download Data